Hyper Corporation Continues Restructuring and Fundraising… Net Loss and Financial Burden Remain
Accelerated restructuring: Multiple asset transfers, merger (GiftLetter), capital increase (~₩15B) via third-party allotment, and change of top shareholder to JK New Technology Investment Fund No.12.
Consolidated Q1 performance deteriorated: Revenue ₩23.5B (up from ₩18.9B YoY), operating loss improved to ₩0.47B (from ₩2.84B), but net loss of ₩2.36B (vs net profit of ₩0.48B in Q1 2025).
Financial strain: Debt ratio 226%, net debt ₩30.2B, convertible bonds outstanding ₩26B. Put option redemption risk ahead.
Bio pipeline: Alzheimer's diagnostic kit (QPLEX Alz Plus) under new health technology assessment (final approval expected Aug 2026). Non-opioid analgesic (MDR-652) seeking technology transfer.
Tech business growth: Acquisition and merger of subsidiary GiftLetter completed in May 2026. B2B expansion via mobile gift certificate platform 'Gift-N'.
No dividend: Accumulated losses and priority on financial improvement; no dividend plan.